28 related articles for article (PubMed ID: 38503892)
1. Uterine sarcoma with posterior reversible encephalopathy syndrome associated with pazopanib.
Tatsumichi T; Tanaka H; Okazaki T; Takahashi K; Suzuki K; Kawakita K; Houchi H; Kuroda Y; Kosaka S
J Clin Pharm Ther; 2021 Feb; 46(1):223-226. PubMed ID: 33044009
[TBL] [Abstract][Full Text] [Related]
2. Mechanisms Underlying Vascular Endothelial Growth Factor Receptor Inhibition-Induced Hypertension: The HYPAZ Trial.
Mäki-Petäjä KM; McGeoch A; Yang LL; Hubsch A; McEniery CM; Meyer PAR; Mir F; Gajendragadkar P; Ramenatte N; Anandappa G; Santos Franco S; Bond SJ; Schönlieb CB; Boink Y; Brune C; Wilkinson IB; Jodrell DI; Cheriyan J
Hypertension; 2021 May; 77(5):1591-1599. PubMed ID: 33775123
[TBL] [Abstract][Full Text] [Related]
3. Prospective observational study on Pazopanib in patients treated for advanced or metastatic renal cell carcinoma in countries in Asia Pacific, North Africa, and Middle East regions: PARACHUTE study.
Erman M; Biswas B; Danchaivijitr P; Chen L; Wong YF; Hashem T; Lim CS; Karabulut B; Chung HJ; Chikatapu C; Ingles S; Slimane K; Kanesvaran R
BMC Cancer; 2021 Sep; 21(1):1021. PubMed ID: 34521387
[TBL] [Abstract][Full Text] [Related]
4. First-line pazopanib in intermediate- and poor-risk patients with metastatic renal cell carcinoma: Final results of the FLIPPER trial.
Staehler M; Panic A; Goebell PJ; Merling M; Potthoff K; Herrmann E; de Geeter P; Vannier C; Hogrefe C; Marschner N; Grünwald V
Int J Cancer; 2021 Feb; 148(4):950-960. PubMed ID: 32738823
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness of pazopanib for local and lung metastases in Stewart-Treves syndrome.
Hayashi M; Makino T; Mori N; Mizawa M; Shimizu T
Eur J Dermatol; 2020 Feb; 30(1):68-69. PubMed ID: 32250262
[No Abstract] [Full Text] [Related]
6. Nanoparticle-based inhibition of vascular endothelial growth factor receptors alleviates osteoarthritis pain and cartilage damage.
Ma K; Pham T; Wang J; O-Sullivan I; DiCamillo A; Du S; Mwale F; Farooqui Z; Votta-Velis G; Bruce B; van Wijnen AJ; Liu Y; Im HJ
Sci Adv; 2024 Feb; 10(7):eadi5501. PubMed ID: 38354243
[TBL] [Abstract][Full Text] [Related]
7. Nanoparticle-based pazopanib shows promise in OA.
Kelsey R
Nat Rev Rheumatol; 2024 May; 20(5):253. PubMed ID: 38503892
[No Abstract] [Full Text] [Related]
8. Pazopanib: a Review in Advanced Renal Cell Carcinoma.
Frampton JE
Target Oncol; 2017 Aug; 12(4):543-554. PubMed ID: 28664385
[TBL] [Abstract][Full Text] [Related]
9. [Pharmacological profile and clinical results in advanced soft tissue sarcoma patients of pazopanib hydrochloride (Votrient(®))].
Arai H; Fukasawa N; Ueta F
Nihon Yakurigaku Zasshi; 2013 Jan; 141(1):37-42. PubMed ID: 23302947
[No Abstract] [Full Text] [Related]
10. Pazopanib for the treatment of renal cell carcinoma.
Welsh SJ; Fife K
Future Oncol; 2015; 11(8):1169-79. PubMed ID: 25832874
[TBL] [Abstract][Full Text] [Related]
11. Pazopanib: an antiangiogenic drug in perspective.
Castaneda CA; Gomez HL
Future Oncol; 2009 Nov; 5(9):1335-48. PubMed ID: 19903063
[TBL] [Abstract][Full Text] [Related]
12. (Pre-)clinical pharmacology and activity of pazopanib, a novel multikinase angiogenesis inhibitor.
Hamberg P; Verweij J; Sleijfer S
Oncologist; 2010; 15(6):539-47. PubMed ID: 20511320
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]